A subtle loss: visual and anatomic changes in HIV retinopathy

Article

New technology is allowing clinicians, for the first time, to study the subtle structural changes that cause progression of this disease.

Diagnosing HIV retinopathy

HIV retinopathy is an ischaemic microangiopathy that leads to damage of inner retinal structures including the vasculature and ganglion cells. Clinically, HIV retinopathy is diagnosed by the presence of intra-retinal haemorrhages and soft retinal exudates (cotton wool spots) in patients with low CD4 T-lymphocyte cell counts (<100 or 1.0 x 109/L) in the absence of infectious retinitis. Upon a patient's immune recovery, HIV retinopathy usually resolves within three months. However, if a patient's immune status is not recovered, these signs may persist or worsen while the CD4 cell count remains low.

OCT allows imaging of subtle changes

The advent of more sophisticated retinal imaging technology has opened up new possibilities for studying structural changes in HIV retinopathy. Many of these instruments are already in clinical use for glaucoma and other retinal diseases.

One hypothesis to explain vision loss is that it may be caused by permanent infarctions of the retinal nerve fibre layer from previously resolved cotton wool spots, areas of retinal capillary dropout, or both. Using OCT, we have been able to demonstrate visible inner retinal structural changes long after cotton wool spots have disappeared on ophthalmoscopic examinations. The inner retinal tissue in the area of cotton wool spots remains more dense than adjacent retina (hyper-reflective sign), which may mean chronic oedema or glial transformation of the tissue. It may be that such a cumulative damage from multiple infarctions and haemorrhages can finally lead to changes in the nerve fibre layer of the retina. Fortunately, the progress in technology now means we have the advantage of detecting some of these changes in vivo.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.